Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (191)	2/15/2007 2:17:56 PM
From: tuck	Read Replies (1) \| Respond to of 507

Optimism pretty firm, but share price probably won't explode. This is why I think this is good candidate for writing strategies. I doubt the patent lawsuit effects Pfizer's launch activities and plans. It just got started and will drag on for years (both launch and lawsuit, hah!). IMO, a tactic by NVO to try and salvage something from the ARDM program, once neck and neck with NKTR, now back in the peloton, wheezing. Cheers, Tuck